Critères d’évaluation d’efficacité d’un traitement de première ligne dans la sclérose en plaques en pratique courante

Gasperini, 2019, Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge, Neurology, 92, 180, 10.1212/WNL.0000000000006810 Thompson, 2018, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, 17, 162, 10.1016/S1474-4422(17)30470-2 E Leray, J Roux, F Rollot, R Casey, SJ De, D Laplaud, S Vukusic. Quelle utilisation des traitements de fond chez des patients ayant une sclérose en plaques rémittente en France sur la période 1990-2017 ? Étude des données de l’Observatoire français de la SEP. Revue d’Epidémiologie et de Santé Publique 66[4], S227. 1-6-2018. Brown, 2019, Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis, JAMA, 321, 175, 10.1001/jama.2018.20588 Harding, 2019, Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis, JAMA Neurol, 76, 536, 10.1001/jamaneurol.2018.4905 Le Page, 2018, Induction or escalation therapy for patients with multiple sclerosis?, Rev Neurol (Paris), 174, 449, 10.1016/j.neurol.2018.04.004 Brisset, 2020, New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions, J Neuroradiol, 47, 250, 10.1016/j.neurad.2020.01.083 Montalban, 2018, ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis, Mult Scler, 24, 96, 10.1177/1352458517751049 Rae-Grant, 2018, Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology, Neurology, 90, 777, 10.1212/WNL.0000000000005347 Vermersch, 2019, Expert opinion: criteria for second-line treatment failure in patients with multiple sclerosis, Mult Scler Relat Disord, 36, 101406, 10.1016/j.msard.2019.101406 Prosperini, 2020, Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis, J Neurol Neurosurg Psychiatry, 91, 271, 10.1136/jnnp-2019-322348 Rio, 2018, Disability progression markers over 6–12 years in interferon-beta-treated multiple sclerosis patients, Mult Scler, 24, 322, 10.1177/1352458517698052 Bermel, 2013, Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta, Ann Neurol, 73, 95, 10.1002/ana.23758 Stewart, 2017, Contribution of different relapse phenotypes to disability in multiple sclerosis, Mult Scler, 23, 266, 10.1177/1352458516643392 Cotton, 2015, OFSEP, a nationwide cohort of people with multiple sclerosis: consensus minimal MRI protocol, J Neuroradiol, 42, 133, 10.1016/j.neurad.2014.12.001 Giovannoni, 2015, Is it time to target no evident disease activity (NEDA) in multiple sclerosis?, Mult Scler Relat Disord, 4, 329, 10.1016/j.msard.2015.04.006 Kunchok, 2020, Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score, Mult Scler Matta, 2016, No evidence of disease activity in multiple sclerosis patients, Expert Rev Neurother, 16, 1279, 10.1080/14737175.2016.1202763 Rio, 2009, Measures in the first year of therapy predict the response to interferon beta in MS, Mult Scler, 15, 848, 10.1177/1352458509104591 Sormani, 2013, Defining and scoring response to IFN-beta in multiple sclerosis, Nat Rev Neurol, 9, 504, 10.1038/nrneurol.2013.146 Sormani, 2016, Assessing response to interferon-beta in a multicenter dataset of patients with MS, Neurology, 87, 134, 10.1212/WNL.0000000000002830 Sormani, 2017, Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO, Neurol Neuroimmunol Neuroinflamm, 4, e379, 10.1212/NXI.0000000000000379 Giovannoni, 2018, A brief history of NEDA, Mult Scler Relat Disord, 20, 228, 10.1016/j.msard.2017.07.011 Giovannoni, 2018, Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm, Curr Opin Neurol, 31, 233, 10.1097/WCO.0000000000000561 Hegen, 2018, No evidence of disease activity – is it an appropriate surrogate in multiple sclerosis?, Eur J Neurol, 25, 1107, 10.1111/ene.13669 Lu, 2018, The evolution of “No Evidence of Disease Activity” in multiple sclerosis, Mult Scler Relat Disord, 20, 231, 10.1016/j.msard.2017.12.016 Goodin, 2019, Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b, Mult Scler, 25, 837, 10.1177/1352458518773511 Rotstein, 2015, Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort, JAMA Neurol, 72, 152, 10.1001/jamaneurol.2014.3537 Cree, 2016, Long-term evolution of multiple sclerosis disability in the treatment era, Ann Neurol, 80, 499, 10.1002/ana.24747 Rotstein, 2019, Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis, Nat Rev Neurol, 15, 287, 10.1038/s41582-019-0170-8 Parks, 2017, NEDA treatment target? No evident disease activity as an actionable outcome in practice, J Neurol Sci, 383, 31, 10.1016/j.jns.2017.10.015 Ntranos, 2016, Diagnostic criteria, classification and treatment goals in multiple sclerosis: the chronicles of time and space, Curr Neurol Neurosci Rep, 16, 90, 10.1007/s11910-016-0688-8 Mayssam, 2020, “No evidence of disease activity”: is it an aspirational therapeutic goal in multiple sclerosis?, Mult Scler Relat Disord, 40, 101935, 10.1016/j.msard.2020.101935 Giovannoni, 2017, “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis, Mult Scler, 23, 1179, 10.1177/1352458517703193 Wattjes, 2015, Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – establishing disease prognosis and monitoring patients, Nat Rev Neurol, 11, 597, 10.1038/nrneurol.2015.157 Dadalti, 2015, Why some of us do not like the expression “no evidence of disease activity” (NEDA) in multiple sclerosis, Mult Scler Relat Disord, 4, 383, 10.1016/j.msard.2015.06.009 Rio, 2015, Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: no, Mult Scler, 21, 132, 10.1177/1352458514565415 Smith, 2017, Therapeutic targets for multiple sclerosis: current treatment goals and future directions, Neurotherapeutics, 14, 952, 10.1007/s13311-017-0548-5 Sormani, 2013, Scoring treatment response in patients with relapsing multiple sclerosis, Mult Scler, 19, 605, 10.1177/1352458512460605 Glanz, 2007, Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis, Mult Scler, 13, 1004, 10.1177/1352458507077943 Pitteri, 2017, Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study, Mult Scler, 23, 848, 10.1177/1352458516665496 Coyle, 2017, Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study, Mult Scler Relat Disord, 17, 107, 10.1016/j.msard.2017.07.006 D’Amico, 2019, Review: patient-reported outcomes in multiple sclerosis care, Mult Scler Relat Disord, 33, 61, 10.1016/j.msard.2019.05.019 Vermersch, 2020, An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017, Mult Scler Relat Disord, 46, 102521, 10.1016/j.msard.2020.102521 Coyle, 2018, Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: results from the global Phase 4 Teri-PRO study in routine clinical practice, Mult Scler Relat Disord, 26, 211, 10.1016/j.msard.2018.09.017 Coles, 2012, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, Lancet, 380, 1829, 10.1016/S0140-6736(12)61768-1 Coyle, 2013, Switching therapies in multiple sclerosis, CNS. Drugs, 27, 239, 10.1007/s40263-013-0042-5 O’Connor, 2011, Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, 365, 1293, 10.1056/NEJMoa1014656 Ziemssen, 2016, Optimizing treatment success in multiple sclerosis, J Neurol, 263, 1053, 10.1007/s00415-015-7986-y Trojano, 2017, Treatment decisions in multiple sclerosis – insights from real-world observational studies, Nat Rev Neurol, 13, 105, 10.1038/nrneurol.2016.188